NDA 205838 · Ucb INC
Briviact
Brivaracetam · Oral
Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Feb 18, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
52
27 Phase 3, 0 recruiting
FAERS reports
9,327
7,450 serious, 467 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2026.
BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. ( 1 )
Mechanism: The precise mechanism by which BRIVIACT exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2021 Supplement 6 · Efficacy LetterLabel
- May 10, 2018 Supplement 3 · Efficacy LabelLetter
- Sep 14, 2017 Supplement 2 · Efficacy LabelLetter
- Feb 18, 2016 Original approval · Type 3 - New Dosage Form ReviewFederal Register NoticeLetter
1 products under this application
- BRIVIACT · BRIVARACETAM 10MG/ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Brivaracetam" as an intervention, any sponsor and status, largest first.
- Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From EpilepsyPivotal-lookingCompleted
UCB PharmaUCB
NCT00175916 · 853 participants · Start Sep 2005 · Primary completion May 2019
Drug: Brivaracetam (ucb 34714) · For: Epilepsy
Sites: San Francisco, California; Gainesville, Florida; Charlottesville, Virginia · 153 sites in all
- Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset SeizuresPivotal-lookingCompleted
UCB PharmaUCB
NCT01261325 · 768 participants · Start Dec 2010 · Primary completion May 2014
Drug: Placebo; Brivaracetam and 2 more · For: Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 207 sites in all
- Brivaracetam Safety and Efficacy Follow-up Study in Subjects With EpilepsyPivotal-lookingCompleted
NCT01339559 · 767 participants · Start May 11, 2011 · Primary completion Apr 18, 2019
Drug: Brivaracetam · For: Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 184 sites in all
NCT00150800 · 668 participants · Start Jan 2006 · Primary completion Sep 2017
Drug: Brivaracetam · For: Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 100 sites in all
- Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From EpilepsyPivotal-lookingCompleted
NCT00504881 · 480 participants · Start Oct 2007 · Primary completion Nov 2008
Drug: Placebo; Brivaracetam · For: Epilepsy
Sites: Graz, Austria; Innsbrick, Austria; Linz, Austria · 61 sites in all
- A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With EpilepsyPivotal-lookingCompleted
NCT03083665 · 449 participants · Start Aug 22, 2017 · Primary completion Jun 30, 2022
Drug: Placebo; Brivaracetam · For: Partial Seizures With or Without Secondary Generalization; Epilepsy
Sites: Beijing, China; Changchun, China; Chengdu, China · 94 sites in all
- Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresPivotal-lookingCompleted
UCB PharmaUCB
NCT00464269 · 400 participants · Start Sep 2007 · Primary completion Dec 2008
Drug: Brivaracetam 2.5 mg; Brivaracetam 10 mg and 1 more · For: Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 69 sites in all
- Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresPivotal-lookingCompleted
NCT00490035 · 399 participants · Start Sep 2007 · Primary completion Feb 2009
Drug: Brivaracetam; Brivaracetam and 1 more · For: Epilepsy
Sites: Ghent, Belgium; La Louvière, Belgium; Liège, Belgium · 76 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure3,353
- off label use1,195
- drug ineffective1,051
- fatigue600
- therapy interrupted545
- somnolence532
- overdose516
- dizziness479
- product availability issue403
- fall381
- generalised tonic-clonic seizure360
- epilepsy352
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 107 |
| 2017 | 231 |
| 2018 | 435 |
| 2019 | 773 |
| 2020 | 692 |
| 2021 | 931 |
| 2022 | 1,034 |
| 2023 | 1,205 |
| 2024 | 1,261 |
| 2025 | 1,396 |
| 2026 | 1,253 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Briviact* (Brivaracetam)
2024 spending
$220M
Beneficiaries
15,497
137,123 claims
Per beneficiary
$14,182
$23.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $97,878,890 |
| 2021 | $119,191,699 |
| 2022 | $149,528,079 |
| 2023 | $184,375,922 |
| 2024 | $219,770,911 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
Steinhoff BJ, Klein P, Klitgaard H, et al. · Epilepsy Behav 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S, Trinka E, Zaccara G, et al. · Drugs 2022 · Systematic Review, Network Meta-Analysis
- Neurodevelopmental and Functional Outcomes Following In Utero Exposure to Antiseizure Medication: A Systematic Review.
Honybun E, Cockle E, Malpas CB, et al. · Neurology 2024 · Systematic Review
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
Inoue Y, Tiamkao S, Zhou D, et al. · Epilepsia Open 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- [Brivaracetam in the treatment of patients with epilepsy].
Karlov VA, Vlasov PN, Zhidkova IA, et al. · Zh Nevrol Psikhiatr Im S S Korsakova 2017 · Meta-Analysis, Review
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.